ArticleFood science & nutrition2025
Pomegranate-Derived Exosome-Like Nanovesicles Containing Ellagic Acid Alleviate Gut Leakage and Liver Injury in MASLD.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Fruit- and Vegetable-Derived Exosome-like Nanovesicles: A Review.Foods (Basel, Switzerland) · 2026Review
- Current Advances in Liver-Targeted Drug Delivery: Synthetic, Biological, and Biomimetic Platforms.International journal of molecular sciences · 2026Review
- Plant-Derived Nanovesicles: A Comprehensive Review from Isolation to Clinical Translation-Unlocking Natural Nanocarriers for Biomedical Applications.Biomolecules · 2026Review
- Pomegranate peel-derived exosome-like nanoparticles: A discarded treasure trove for colorectal cancer treatment.Oncology letters · 2026Article
- Plant-derived nanocarriers & nanostructures for barrier-defined translation: a comprehensive review of mechanisms, targets, and translation.Journal of nanobiotechnology · 2026Review
- Article
- Engineered bacterial extracellular vesicles as next-generation precision postbiotics: strategies, challenges and prospects.Extracellular vesicles and circulating nucleic acids · 2026Review
- Plant-Derived Exosome-Like Nanoparticles in Neurodegenerative Diseases: From Dual Bioactive-Delivery Roles to Translational Challenges.International journal of nanomedicine · 2026Review
- Plant-Derived Exosome-Like Nanoparticles: Mechanisms of Cross-Kingdom Regulation and Perspectives as Natural Drug Carriers for Disease Treatment.International journal of nanomedicine · 2026Review
- Harnessing plant-derived extracellular vesicles in advanced biomaterials: from structural scaffolds to responsive systems for next-generation wound therapeutics.Burns & trauma · 2026Review
- Nanotherapeutic Strategies for MASLD: From Pathological Mechanisms to Targeted Delivery Systems.International journal of nanomedicine · 2026Review
- Osteogenic Effects of Brown AlgaePreventive nutrition and food science · 2025Article
- Dietary Strategies in the Prevention of MASLD: A Comprehensive Review of Dietary Patterns Against Fatty Liver.Metabolites · 2025Review
- Therapeutic Potential of Ellagic Acid in Liver Diseases.Molecules (Basel, Switzerland) · 2025Review
- Plant Exosome-Loaded Intelligent Hydrogels for Osteoporotic Bone Regeneration: Mechanisms and Applications.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosome-like nanovesicles derived from plants (PENs) harbor a spectrum of bioactive compounds, including proteins, lipids, nucleic acids (such as miRNAs and mRNAs), offering therapeutic advantages for a variety of diseases. This investigation assesses the utility of pomegranate-derived exosome-like nanovesicles (PNVs) in both preventing and treating complications such as liver damage and increased intestinal permeability found in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Utilizing Transmission Electron Microscopy (TEM) and Nanoparticle Tracking Analysis (NTA), we successfully isolated PNVs and characterized their structural properties. Upon administration in a live model, these nanovesicles were efficiently distributed to critical organs, including the liver and intestines, demonstrating biocompatibility by avoiding toxic effects. Remarkably, these vesicles were enriched with ellagic acid, known for its strong antioxidant capabilities. In a controlled MASLD mouse study, treatment with PNVs significantly lowered serum endotoxin levels, reinforced intestinal barrier functions, and altered the gut microbiota profile favorably. Furthermore, the application of PNVs reduced oxidative stress and the presence of fibrosis markers in the liver to normal levels. These results indicate that PNVs could be a viable option for addressing MASLD, enhancing intestinal integrity, reducing liver injury, and diminishing fibrosis through the modulation of the gut-liver axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.